About us
The InnoSIGN team is committed to transform cancer care by enabling personalized targeted therapy options through OncoSIGNal pathway activity profiling. Our team has a wealth of experience in bringing innovative diagnostic solutions to the market.
revolutionizing precision medicine
Board of Directors
Allan May
Chairman - Life Science Angels
Harrold van Barlingen
Thuja Capital
Shaun Rodriguez
Casdin Capital
Mark Oldroyd
Independent Board Member
Paul van de Wiel
CEO InnoSIGN
Jeroen Siemes
Observer BOM
Benno Tieke
Observer PhilipsMeet the Team
